百多力 卓越生活

BIOTRONIK的诊断（DX）技术已经达到了一个非凡的里程碑——全球范围内已有10万台DX设备被植入.¹⁴ 自2009年以来，在大量临床研究数据的支撑下，DX已积累了广泛的证据，这一成就凸显了我们对创新及患者关怀坚定不移的执着精神.

作为配备漂浮心房电极的独特的单腔ICD系统，DX ICD具有以下功能：:

• 能够提供有关房性心律失常的可靠、及时信息，并能尽早检测出房颤.^{2, 3, 4, 5, 6}
• 有助于临床医生长期监测房颤负荷.³

结合百多力家庭监护系统（BIOTRONIK Home Monitoring®）以及可选的百多力患者应用程序（BIOTRONIK Patient App），这一房颤管理解决方案能够对ICD患者进行全面评估，并使得能够更早地、基于充分信息做出决策.³

In November 2025, BIOTRONIK brought together more than 120 experts at the third Digital Heart Summit in Berlin, under the scientific leadership of Prof. Gerhard Hindricks from DHZC Berlin, to discuss the future of digitally supported cardiac care. The focus was on AI, remote monitoring, and active patient engagement. An interactive Vision Tour showcased the latest technologies that are increasingly being adopted in clinical practice. The summit provides an annual global platform for exchanging ideas on digitalization in cardiology. The recordings are available online now. 

Solia CSP S is specifically designed for conduction system pacing and intended to simplify implant handling without compromising patient outcomes.

Now available as part of the BIOTRONIK CSP portfolio – for smooth and efficient CSP procedures.

BIOTRONIK and the University of Sydney have signed a Memorandum of Understanding (MoU) to jointly advance digital and connected health innovations through 2028.

The collaboration aims to co-design solutions that address real-world clinical needs and hopes to benefit patients particularly in remote or underserved regions with limited access to care.

心脏疾病是全球女性死亡的主要原因。然而，女性的心脏健康问题常常被忽视。

这就是为什么现在应该关注女性心脏疾病问题。在百多力，我们齐心协力致力于推进女性心脏疾病的护理。加入我们的活动，加强合作、普及知识，引领并改变现状，让心脏更健康！

与医生紧密合作并倾听他们的需求，我们共同开发了完整的传导系统起搏（CSP）解决方案，包括世界上第一个也是唯一一个获得批准的核磁兼容CSP系统¹, 并提供全面的培训和专业的技术支持。

BIOTRONIK的CSP系统由三个经过验证的组件构成： 

• Selectra 3D –提供多个长度和弯形的鞘管，确保卓越的操作性²
• Solia S – LBBAP中最受欢迎选择的钢丝支撑导线³, 提供增强的稳定性²
• Amvia –第一个获得LBBAP认证的起搏器家族¹

凭借协同开发的系统以及实用的培训项目，BIOTRONIK的CSP解决方案让您能够满怀信心且轻松地实现LBBAP。